TY - JOUR
T1 - Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy
AU - Becerra-Báez, Elayne Irene
AU - Meza-Toledo, Sergio Enrique
AU - Muñoz-López, Paola
AU - Flores-Martínez, Luis Fernando
AU - Fraga-Pérez, Karla
AU - Magaño-Bocanegra, Kevin Jorge
AU - Juárez-Hernández, Uriel
AU - Mateos-Chávez, Armando Alfredo
AU - Luria-Pérez, Rosendo
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/9
Y1 - 2022/9
N2 - Over a century ago, bacterial extracts were found to be useful in cancer therapy, but this treatment modality was obviated for decades. Currently, in spite of the development and advances in chemotherapies and radiotherapy, failure of these conventional treatments still represents a major issue in the complete eradication of tumor cells and has led to renewed approaches with bacteria-based tumor therapy as an alternative treatment. In this context, live-attenuated bacteria, particularly Salmonella enterica, have demonstrated tumor selectivity, intrinsic oncolytic activity, and the ability to induce innate or specific antitumor immune responses. Moreover, Salmonella enterica also has strong potential as a delivery system of tumor-associated antigens, cytotoxic molecules, immunomodulatory molecules, pro-apoptotic proteins, and nucleic acids into eukaryotic cells, in a process known as bactofection and antitumor nanoparticles. In this review, we present the state of the art of current preclinical and clinical research on the use of Salmonella enterica as a potential therapeutic ally in the war against cancer.
AB - Over a century ago, bacterial extracts were found to be useful in cancer therapy, but this treatment modality was obviated for decades. Currently, in spite of the development and advances in chemotherapies and radiotherapy, failure of these conventional treatments still represents a major issue in the complete eradication of tumor cells and has led to renewed approaches with bacteria-based tumor therapy as an alternative treatment. In this context, live-attenuated bacteria, particularly Salmonella enterica, have demonstrated tumor selectivity, intrinsic oncolytic activity, and the ability to induce innate or specific antitumor immune responses. Moreover, Salmonella enterica also has strong potential as a delivery system of tumor-associated antigens, cytotoxic molecules, immunomodulatory molecules, pro-apoptotic proteins, and nucleic acids into eukaryotic cells, in a process known as bactofection and antitumor nanoparticles. In this review, we present the state of the art of current preclinical and clinical research on the use of Salmonella enterica as a potential therapeutic ally in the war against cancer.
KW - Salmonella enterica
KW - cancer therapy
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85137786093&partnerID=8YFLogxK
U2 - 10.3390/cancers14174224
DO - 10.3390/cancers14174224
M3 - Artículo de revisión
C2 - 36077761
AN - SCOPUS:85137786093
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 17
M1 - 4224
ER -